Teladoc, Inc. (NYSE:TDOC)‘s stock had its “buy” rating reaffirmed by investment analysts at Piper Jaffray Companies in a research note issued on Friday, July 14th. They currently have a $32.00 price objective on the health services provider’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 5.44% from the company’s previous close.
Other research analysts also recently issued reports about the stock. Canaccord Genuity restated a “buy” rating and set a $34.00 target price on shares of Teladoc in a research report on Wednesday, May 24th. Robert W. Baird restated a “buy” rating and set a $28.00 target price on shares of Teladoc in a research report on Tuesday, May 9th. Chardan Capital boosted their target price on shares of Teladoc from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. TheStreet raised shares of Teladoc from a “d” rating to a “c-” rating in a report on Thursday, April 13th. Finally, Craig Hallum cut shares of Teladoc from a “buy” rating to a “hold” rating and lifted their price objective for the company from $28.00 to $32.00 in a report on Friday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. Teladoc presently has an average rating of “Buy” and an average target price of $35.55.
Teladoc (NYSE TDOC) traded down 1.14% during midday trading on Friday, hitting $30.35. The stock had a trading volume of 682,680 shares. The firm has a 50-day moving average of $33.88 and a 200 day moving average of $27.52. Teladoc has a 52-week low of $14.00 and a 52-week high of $36.90. The firm’s market capitalization is $1.72 billion.
Teladoc (NYSE:TDOC) last posted its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The company’s revenue for the quarter was up 68.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. On average, equities analysts forecast that Teladoc will post ($1.47) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Stock Rating Reaffirmed by Piper Jaffray Companies” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2017/08/13/teladocs-tdoc-buy-rating-reiterated-at-piper-jaffray-companies-2-updated-updated-updated.html.
In other news, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the completion of the sale, the insider now owns 33,008 shares of the company’s stock, valued at $1,020,607.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 13,389 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $32.89, for a total transaction of $440,364.21. Following the sale, the chief executive officer now directly owns 831,650 shares of the company’s stock, valued at approximately $27,352,968.50. The disclosure for this sale can be found here. Insiders have sold 207,186 shares of company stock valued at $6,122,950 in the last three months. Corporate insiders own 5.94% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Ameriprise Financial Inc. boosted its stake in shares of Teladoc by 125.7% in the first quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock valued at $3,288,000 after buying an additional 73,231 shares in the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Teladoc during the first quarter valued at about $6,411,000. Blair William & Co. IL acquired a new stake in shares of Teladoc during the first quarter valued at about $218,000. Swiss National Bank boosted its stake in shares of Teladoc by 37.5% in the first quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock valued at $1,420,000 after buying an additional 15,500 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock valued at $6,309,000 after buying an additional 9,146 shares in the last quarter. 95.88% of the stock is owned by institutional investors.
About Teladoc
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
